Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness
-
Upload
ivor-cervantes -
Category
Documents
-
view
32 -
download
2
description
Transcript of Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness
![Page 1: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/1.jpg)
Stroke Prevention With the NOACs—
From Guidelines to Cost-Effectiveness
![Page 2: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/2.jpg)
Warfarin-Related Costs in Denmark
![Page 3: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/3.jpg)
NICE Guidelines: Reassessing Anticoagulation
![Page 4: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/4.jpg)
Warfarin and the Cost of Bleeding
![Page 5: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/5.jpg)
Warfarin-Related Intracerebral Bleeding and Ischemic Stroke in
Germany
![Page 6: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/6.jpg)
Non-Vitamin K Oral Anticoagulants:Stroke Outcomes vs Warfarin
![Page 7: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/7.jpg)
Optimal Stroke Prevention in AF: Populations in Need of Treatment
![Page 8: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/8.jpg)
Patient and Physician Attitudes on Stroke Prevention and Bleeding in
AF
![Page 9: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/9.jpg)
Guidelines for the Management of AF
![Page 10: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/10.jpg)
CHA2DS2-VASc: Risk Factors for Stroke
![Page 11: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/11.jpg)
Stroke Prevention in AF: CHA2DS2-VASc
![Page 12: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/12.jpg)
2012 ESC AF Management Guidelines: Using CHA2DS2-VASc
![Page 13: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/13.jpg)
Stroke Risk Reduction in AF With Anticoagulants and Aspirin
![Page 14: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/14.jpg)
Mean TTR in SPAF Patients on Warfarin: Country Variability in the RE-LY Trial*
![Page 15: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/15.jpg)
Warfarin Median TTR in the NOAC Trials
![Page 16: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/16.jpg)
Warfarin 30-Day Stroke Rate: UK Clinical Practice Research Datalink
Analysis
![Page 17: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/17.jpg)
FDA Drug Safety Communication on Dabigatran: Outcomes vs Warfarin
![Page 18: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/18.jpg)
Danish National Registry: 4978 Patients With AF Treated With Dabigatran
![Page 19: Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness](https://reader036.fdocuments.in/reader036/viewer/2022062517/56813046550346895d95ee65/html5/thumbnails/19.jpg)
Thank you for participating in this activity.